John Reed (Endpoints JPM19, Jeff Rumans)

Com­ing up be­hind the mR­NA lead­ers, Sanofi, GSK piv­ot in­to PhI/II tri­al for their tra­di­tion­al tech ap­proach to a Covid-19 vac­cine. This race is­n't over yet

Right now all eyes are on a pair of cut­ting-edge mR­NA vac­cines cur­rent­ly cruis­ing through fast Phase III Covid-19 tri­als with a shot at …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.